Ms Raya Yashooa | Molecular biology, Genetics, Neuroscience, Cancer Research | Best Researcher Award

Ms Raya Yashooa | Molecular biology, Genetics, Neuroscience, Cancer Research | Best Researcher Award

Lecture Department of Biology, College of Education for Pure Science, at University of Al-Hamdaniya ,Iraq

Raya Khalid Yousif is an Iraqi molecular biologist with extensive expertise in microbiology, genetics, and laboratory research. With over a decade of experience in medical laboratory sciences, she is a lecturer, researcher, and skilled laboratory specialist. She has contributed significantly to Alzheimer’s disease research, infectious disease studies, and microbiological diagnostics.

Profile

orcid

scopus

Early Academic Pursuits 📚

Born on December 22, 1991, in Erbil, Iraq, Raya Khalid Yousif embarked on an academic journey driven by curiosity and dedication to the biological sciences. She earned her Bachelor of Science in Biology from the University of Baghdad in 2013, securing a distinguished sixth-ranking position. Her passion for molecular biology led her to pursue a Master of Science in Molecular Biology at Salahaddin University, Erbil, which she successfully completed in 2023. Further strengthening her academic expertise, she attended a Pedagogy course at the Lebanese French University in 2023, enhancing her teaching and research methodologies.

Professional Endeavors 🔬

With over a decade of experience in molecular biology and laboratory sciences, Raya has contributed significantly to both academia and applied research. Since February 2024, she has been serving as a Lecturer in Medical Microbiology at Knowledge University on a part-time basis. Alongside her academic role, she has been a volunteer researcher at the General Directorate of Scientific Research Center, Salahaddin University-Erbil, since April 2023, demonstrating her commitment to advancing scientific knowledge.

Her expertise extends to laboratory work, having served as a Laboratory Assistant at Catholic University-Erbil (2021-2022) and working at the Ankawa Specialized Laboratory for over a decade. These experiences have honed her practical skills in molecular diagnostics, microbiology, and clinical research.

Contributions and Research Focus 🔎

Raya Khalid Yousif specializes in molecular biology techniques, including RNA/DNA extraction, primer design, Real-Time qPCR, conventional PCR, gene cloning, and ELISA-based diagnostics. Her research has covered diverse areas such as neuroscience, oncology, genetics, molecular immunology, bacteriology, and clinical hematology. Her expertise in bioinformatics tools like NCBI, Primer3 Input, and Genome Browser enables her to conduct cutting-edge genetic analysis and molecular diagnostics.

She has played a pivotal role in multiple research projects, working extensively with histopathology, bacterial culture analysis (VITEK), and immunoassay techniques. Her work in diagnostic microbiology has contributed to advancements in disease detection and therapeutic strategies, particularly in neurological and infectious diseases.

Accolades and Recognition 🏅

Raya’s contributions to scientific research have been widely recognized. She received a Certificate of Appreciation from the General Directorate of Scientific Research Center, Salahaddin University-Erbil, in 2024 for her valuable contributions. Additionally, she has been an active manuscript reviewer for esteemed journals such as the Journal of Applied Pharmaceutical Science and Medical Science Monitor in 2023.

Her academic excellence extends to language proficiency, having attained an IELTS score of 6.0 in 2023 and undergoing advanced English training at Salahaddin University and AmidEast. She has also attended specialized workshops on Genomics and Proteomics, Infectious Disease Surveillance, and Biomedical Research Techniques, further enriching her expertise.

Impact and Influence 🌍

As an accomplished researcher, Raya has published extensively in renowned scientific journals, making significant contributions to molecular biology, infectious diseases, and neurogenetics. Some of her notable works include:

  • “The miR-146a-5p and miR-125b-5p levels as biomarkers for early prediction of Alzheimer’s disease”
  • “Telomerase Reverse Transcriptase and Telomerase RNA Component Gene Expression as Novel Biomarkers for Alzheimer’s Disease”
  • “The Outbreak of SARS-CoV-2 Variants in Iraqi Kurdistan Region”
  • “Fungal Disease Incidence and Prevalence in Iraq – Preliminary Estimates”
  • “Human ACE and ACE2 Gene Variants and COVID-19 Disease in Iraqi Kurdistan Region” (Accepted for publication)

Her book on microRNAs and telomerase gene expression in Alzheimer’s Disease serves as a valuable resource for researchers exploring neurodegenerative disorders.

Legacy and Future Contributions 🚀

Raya Khalid Yousif’s dedication to research and education positions her as a leading figure in molecular biology and biomedical sciences. With a strong foundation in academia and practical laboratory expertise, she aspires to train future scientists in fields such as molecular microbiology, genetics, clinical immunology, and bioinformatics.

Her unwavering passion for science, coupled with her commitment to humanitarian work—evident in her volunteerism with Together for Human and Environment Association and Community Anti-Drug Collision of Ankawa—reflects her dedication to both scientific and social progress.

Through her relentless pursuit of knowledge and research excellence, Raya continues to pioneer advancements in molecular diagnostics and biomedical research, shaping the future of science and healthcare in Iraq and beyond. 🌟

Publication Top Notes : Molecular biology, Genetics, Neuroscience, Cancer Research

  1. “The miR-146a-5p and miR-125b-5p levels as biomarkers for early prediction of Alzheimer’s disease.”
    • Year: 2022
    • Journal: Human Gene
    • DOI: 10.1016/j.humgen.2022.201129
    • Citations: This study has been referenced in subsequent research exploring microRNA biomarkers in neurodegenerative diseases.
  2. “Telomerase Reverse Transcriptase and Telomerase RNA Component Gene Expression as Novel Biomarkers for Alzheimer’s Disease.”
    • Year: 2022
    • Journal: Cellular and Molecular Biology
    • DOI: 10.14715/cmb/2022.68.9.2
    • Citations: Cited in research focusing on telomerase activity in neurodegenerative conditions.
  3. “Incidence of Candida Species Biofilms in Pediatric Cancer Patients Undergoing Chemotherapy Treatment.”
    • Year: 2022
    • Journal: BioMed Target Journal
    • DOI: 10.59786/bmtj.114
    • Citations: Referenced in studies examining fungal infections in immunocompromised patients.
  4. “Epidemiological Study and Clinical Presentation of Urinary Tract Infection.”
    • Year: 2022
    • Journal: BioMed Target Journal
    • DOI: 10.59786/bmtj.115
    • Citations: Cited in epidemiological research on urinary tract infections.
  5. “MicroRNAs and Telomerase Gene Expression in Alzheimer’s Disease.”
    • Year: 2022
    • Publication Type: Book
    • Link: 978-620-7-47351-9
    • Citations: Serves as a reference in academic discussions on genetic markers in Alzheimer’s disease.
  6. “The Outbreak of SARS-CoV-2 Variants in Iraqi Kurdistan Region.”
    • Year: 2022
    • Journal: The Journal of Infection in Developing Countries
    • DOI: 10.3855/jidc.19351
    • Citations: Included in studies analyzing COVID-19 variant outbreaks.
  7. “Fungal Disease Incidence and Prevalence in Iraq – Preliminary Estimates.”
    • Year: 2024
    • Journal: Journal de Mycologie Médicale
    • DOI: 10.1016/j.mycmed.2024.101516
    • Citations: Referenced in research on fungal disease epidemiology in the Middle East.
  8. “Revolutionizing Medicine: Recent Developments and Future Prospects in Stem Cell Therapy.”
    • Year: 2024
    • Journal: Journal of Stem Cells
    • DOI: 10.1097/JS9.0000000000002109
    • Citations: Cited in discussions on advancements in stem cell research.
  9. “Human ACE and ACE2 Genes Variants and COVID-19 Disease in Iraqi Kurdistan Region.”
    • Year: 2024
    • Journal: Journal of Medical Virology
    • Status: Accepted for publication
    • Citations: Anticipated to contribute to genetic studies related to COVID-19 susceptibility.

 

 

 

 

 

Ms Himani Shah | Cancer cell biology | Best Researcher Award | 1255

Ms Himani Shah | Cancer cell biology | Best Researcher Award

PhD student at Institute for Molecular Bioscience,Australia

Himani Shah is a doctoral candidate in the Institute for Molecular Bioscience (IMB) at The University of Queensland (UQ), Australia, with expertise in cancer research, molecular biology, and biotechnology. She is investigating the cellular mechanisms of G protein-coupled receptors (GPCRs) and their role in cancer progression. Her academic journey has been marked by outstanding performance, earning top grades and recognition. Her research has significant clinical implications for cancer therapy, especially women’s cancers.

Publication Profile

Google Scholar 

Education 🎓

  • Doctor of Philosophy (2021-Present), IMB, UQ, Australia (Supervisors: Prof. David Fairlie & Dr. Junxian Lim). Thesis submission by November 2024.
  • Master of Biotechnology Research Extensive (2019-2020), SCMB, UQ, Australia, GPA 6.56/7.0 (Supervisors: Dr. Roberta Mazzieri, Prof. David Fairlie, Dr. Junxian Lim).
  • Bachelor of Science in Biotechnology (2015-2018), Mithibai College, University of Mumbai, India, GPA 7.0/7.0.

Professional Experience 💼

Himani has gained extensive experience in both research and teaching roles. She is currently a casual academic staff member at SCMB, UQ, tutoring in molecular biology, microbiology, genetics, and biochemistry. Additionally, she has worked as a research tutor at TRI, mentoring high school students in molecular biology techniques. Her practical experience includes extensive laboratory management, training, and mentoring junior researchers.

Research Interests 🔬

Himani’s primary research interests focus on the role of GPCRs in cancer biology. She is investigating how protease-activated receptors, particularly PAR2, influence cancer cell apoptosis and could be leveraged as therapeutic targets, especially in women’s cancers. Her past research projects have also included the role of C3aR in kidney cancer and the characterization of a preclinical metastatic breast cancer model.

Awards and Honors 🏆

  • 2024: HDR IMB Completion Award, Best Poster Presentation at CCDD Symposium.
  • 2023: 3MT IMB Heats – People’s Choice Winner.
  • 2021: SPARQ-ed Research Immersion Scholarship, TRI; Research Training Program UQ Graduate School Scholarship.
  • 2020: Dean’s Commendation for Academic Excellence, UQ.

Achievements 🌟

Himani has achieved success in both research and community engagement. She was awarded People’s Choice at the Three Minute Thesis (3MT) competition at UQ in 2023. Additionally, her participation in various conferences and symposia, both as an oral and poster presenter, highlights her commitment to advancing scientific knowledge.

Upcoming Projects 🚀

Himani’s upcoming work focuses on investigating new therapeutic avenues for women’s cancers, particularly through the modulation of protease-activated receptors. She will also be presenting her research findings at various conferences in 2024, including the European Association for Cancer Research Congress in Rotterdam.

Publication📚

  • Shah, H., Hill, T. A., Lim, J., & Fairlie, D. P. (2023). Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells. Journal of Cell Communication and Signaling, 17, 1293-1307.
  • Shah, H., Fairlie, D. P., & Lim, J. (2024). Protease-activated receptor 2: A promising therapeutic target for women’s cancers. Journal of Pharmacology and Experimental Therapeutics. DOI: 10.1124/jpet.124.002176. Special edition: Breaking barriers in Women’s Cancer Treatment: Innovative Approaches and Experimental Therapeutics.

 

Mr Dharmendra Bhargava | Esophageal cancer and Inflammation | Best Paper Award

Mr Dharmendra Bhargava | Esophageal cancer and Inflammation | Best Paper Award

Senior research Investigator at University of Pennsylvania,United States

Dr. Dharmendra Kumar Bhargava is a Senior Research Investigator at the University of Pennsylvania, specializing in cancer biology, immunology, and molecular medicine. He focuses on understanding the cytoprotective mechanisms in esophageal squamous epithelial cells and their role in cancer progression, particularly the impact of smoking and alcohol. With extensive experience in translational cancer research, he has made significant contributions in areas like tissue repair, cancer metastasis, and immune modulation. His work is guided by a passion for identifying novel therapeutic targets to improve patient outcomes in cancer therapy.
📍 Current Role: Senior Research Investigator, University of Pennsylvania (since 2023)

Publication Profile

Orcid

Scopus

Google Scholar

Education🎓

  • PhD in Life Sciences, Institute of Life Sciences, India (2016). Dissertation: Crosstalk of Estrogen Receptor and Estrogen Receptor-Related Receptor Family Members in Breast Cancer.
  • MSc in Biotechnology, Calicut University, India (2006).
  • BSc in Zoology, Botany, and Chemistry, BSA College, Dr. B.R.A. University, India (2004).
    Research Focus: Breast cancer, estrogen receptors, molecular pathways in cancer.

Professional Experience💼

  • Senior Research Investigator, University of Pennsylvania (2023-Present): Leading research projects focused on the KLF5-p53 axis, wound healing, and immune modulation in cancer and inflammation.
  • Postdoctoral Researcher, University of Pennsylvania (2019-2023): Investigated cytoprotective pathways in esophageal squamous epithelial cells.
  • Postdoctoral Researcher, Baruch S. Blumberg Institute (2019): Developed a prostate cancer prognostic kit using NanoString technology.
  • Researcher, University of Iowa (2017-2019): Studied WDR26’s role in breast tumor growth and lung metastasis.
  • Researcher, University of Houston (2016-2017): Explored GPR110’s involvement in cancer stem cells and HER2-resistant breast cancer.
    Expertise: Cancer research, immunology, tissue repair, drug resistance mechanisms.

Research Interests🔬

Dr. Bhargava’s research spans molecular oncology, immunology, and cellular biology. His work focuses on understanding how cellular pathways, such as the KLF5-p53 axis, regulate cell survival and tissue repair in the context of cancer. He also investigates how these pathways influence immune cell functions and their potential as therapeutic targets for cancer treatment and inflammation.
Key Areas: Cancer biology, molecular signaling, tissue regeneration, immunomodulation.

Awards and Honors🏆

  • Best Poster Presentation, Department of Pharmacology, University of Iowa (2018).
  • National Eligibility Test (NET), Qualified for Lectureship, CSIR-UGC (2006, 2007, 2008).
  • GATE (Graduate Aptitude Test in Engineering), All India Rank 335 (2006) and 261 (2007). Recognition: Awarded for scientific excellence and contributions to pharmacology and cancer research.

Achievements🎯

Dr. Bhargava’s work has led to significant advancements in understanding cancer metastasis and immune responses in inflammatory diseases. His role as a reviewer for prestigious journals such as BMC Cancer and Cellular Signaling highlights his influence in the scientific community. He is also involved in grant reviews and serves as an editor for several scientific journals. Impact: Contributed to scientific knowledge in cancer prognosis, therapeutic development, and immunotherapy.

Upcoming Projects🚀

Dr. Bhargava is currently engaged in several innovative research projects, including exploring the role of KLF5 in extracellular matrix remodeling and its potential as a therapeutic target for wound healing and cancer. He is also investigating the modulation of immune responses in inflammatory conditions, focusing on KLF5’s impact on cytokine production and immune cell signaling. Future Focus: KLF5-targeted therapies, cancer immunotherapy, molecular mechanisms in wound healing.

Publications📚

  1. Bhargava, D.; Rusakow, D.; Zheng, W.; Awad, S.; Katz, J.P.
    KLF5 inhibition initiates epithelial-mesenchymal transition in non-transformed human squamous epithelial cells.
    BBA-Molecular Cell Research, 2024
  2. Jiao, X.; Di Sante, G.; Casimiro, M.; Tantos, A.; Ashton, A.; Li, Z.; Quach, Y.; Bhargava, D.; DiRocco, A.; et al.
    A cyclin D1 intrinsically disordered domain accesses modified histone motifs to govern gene transcription.
    Oncogenesis, 2024;
  3. Dutta, A.; Bhagat, S.; Paul, S.; Katz, J.P.; Sengupta, D.; Bhargava, D.
    Neutrophils in Cancer and Potential Therapeutic Strategies Using Neutrophil-Derived Exosomes.
    Vaccines (Basel), 2023
  4. Yang, Y.; Bhargava, D.; Chen, X.; Zhou, T.; Dursuk, G.; Jiang, W.; Wang, J.; Zong, Z.; Katz, S.I.; Lomberk, G.A.; Urrutia, R.A.; Katz, J.P.
    KLF5 and p53 comprise an incoherent feed-forward loop directing cell-fate decisions following stress.
    Cell Death Dis., 2023
  5. Bhat, R.R.; Yadav, P.; Sahay, D.; Bhargava, D.K.; Creighton, C.J.; Yazdanfard, S.; Al-Rawi, A.; Yadav, V.; Qin, L.; Nanda, S.; Sethunath, V.; Fu, X.; De Angelis, C.; Narkar, V.A.; Osborne, C.K.; Schiff, R.; Trivedi, M.V.
    GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
    Breast Cancer Res Treat., 2018
  6. Sengupta, D.; Bhargava, D.K.; Dixit, A.; Sahoo, B.S.; Biswas, S.; Biswas, G.; Mishra, S.K.
    ERRβ signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells.
    Br J Cancer, 2014
  7. Mishra, S.K.; Sengupta, D.; Sar, P.; Bhargava, D.K.
    Molecular Basis of Aging and Breast Cancer.
    J Cancer Sci Ther, 2013;
  8. Mishra, S.K.; Kanchan, K.; Bhargava, D.K.
    A Review on EZH2 and its Epigenetic Association with Breast Cancer.
    Journal of Cancer Research Updates, 2012;
  9. Sar, P.; Bhargava, D.K.; Sengupta, D.; Rath, B.; Chaudhary, S.; et al.
    In Human Breast Cancer Cells TRβ Competes with ERα for Altering BCl2/Bax Ratio through SMP30-Mediated p53 Induction.
    J Cancer Sci Ther, 2012;